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To the Editor:
Lara et al. have recently reported 
in this Journal a pooled analysis of 
three Southwest Oncology Group trials 
performed in 329 pretreated extensive-
stage small cell lung cancer (SCLC) 
patients aiming to assess whether plat-
inum-sensitivity status is associated 
with survival outcomes.1 Sensitivity 
to first-line chemotherapy has always 
been considered as the main driver of 
second-line therapy outcome in SCLC. 
For this reason, relapsed SCLC has 
been traditionally classified into sensi-
tive and resistant disease according to 
the type of response to first-line ther-
apy and to treatment-free interval (TFI, 
longer or shorter than 60–90 days). 
However, as also underlined by Lara et 
al., this definition was designed many 
years ago and based on a small patient 
series,2 and its validity has been put 
under discussion by some more recent 
studies.1,3
On the basis of this consider-
ations, we have recently performed a 
meta-analysis of six trials of intrave-
nous topotecan-based second-line ther-
apy aimed at validating the currently 
used criteria for defining sensitive/
resistant relapsed SCLC and to assess 
the prognostic impact of sensitive/resis-
tant categories and of other clinical fac-
tors.4 Our study has confirmed the value 
of standard criteria for relapsed SCLC 
outcome prediction. In particular, 
patients with TFI less than 60 days had 
a worse survival outcome; in addition, 
is, cytotoxic agent was included in 
only one of the three trials.
The concept of platinum sensi-
tivity was established based on retro-
spective analysis of the clinical trials 
of second-line chemotherapy with 
cytotoxic agents,2,3,4 and the useful-
ness of the concept has been con-
firmed as long as we used cytotoxic 
agents for second-line treatment.5,6 
The authors’ conclusion may be cor-
rect when noncytotoxic agents, such 
as molecularly targeted agents, are 
used for second-line chemotherapy; 
however, we believe that the tradi-
tional concept still works and should 
be referred to as ever when cytotoxic 
agents are used as second-line treat-
ment in both clinical trial and clinical 
practice settings.
Young Hak Kim, MD, PhD
Michiaki Mishima, MD, PhD
Department of Respiratory Medicine
Graduate School of Medicine
Kyoto University
Kyoto, Japan 
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To the Editor:
Lara et al. have recently reported 
a retrospective study on data from the 
Southwest Oncology Group aiming 
to evaluate the association between 
platinum-sensitivity status and clini-
cal outcome in patients with relapsed 
or refractory small-cell lung cancer. In 
the study, patient-level data from three 
recent Southwest Oncology Group tri-
als for second-line and/or third-line 
extensive-stage small-cell lung cancer 
were pooled and analyzed, and they 
concluded that platinum-sensitivity 
status might no longer be as strongly 
associated with post-progression sur-
vival in the modern era.1
In the article, they mentioned 
a defect of their study in that tri-
als included in their analysis had no 
or little activity, and they stated that 
they, therefore, could not rule out the 
possibility that platinum-sensitivity 
status might influence the outcome 
in patients receiving active therapies; 
however, they did not refer to the bias 
of the included trials in their analysis, 
and we consider that this is a critical 
defect of the study. Trials included 
in their analysis were for bortezo-
mib (proteasome inhibitor), sorafenib 
(vascular endothelial growth factor 
receptor tyrosine kinase inhibitor), 
and topotecan ± aflibercept (vascular 
endothelial growth factor-trap); that 
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patients with liver metastasis and/or 
performance status 2 and/or low albu-
min, regardless of TFI, had a poorer 
survival outlook. Therefore, chemo-
therapy sensitivity was confirmed to be 
a relevant prognostic factor and also to 
be the most important independent fac-
tor able to predict the response to sec-
ond line. Our results are in keeping with 
those of prior studies4 and of a recent 
randomized study comparing amrubi-
cin versus topotecan.5 The large sample 
size (n = 631 patients), the homoge-
neous patient population, and the com-
mon anticancer treatment (intravenous 
topotecan) strengthen the reliability of 
these results.
In contrast to our study, the 
Southwest Oncology Group multivari-
ate analysis showed that elevated lactate 
dehydrogenase, male sex, performance 
status, and weight loss ≥5, but not 
platinum sensitivity (hazard ratio, 1.25; 
p = 0.14), were independently associ-
ated with overall survival. However, 
considering a model that excluded 36 
patients who received more than one 
prior chemotherapy regimen, platinum 
sensitivity showed a positive prognostic 
impact (hazard ratio, 1.34; p = 0.049). 
Despite this, the authors developed a 
scoring system for defining prognostic 
subgroups that did not include plati-
num sensitivity. Possible weaknesses of 
the Southwest Oncology Group study 
include the small sample size (329 
patients) and the variability of second-
line therapies considered (three different 
agents including two inactive nonche-
motherapy drugs used in almost half of 
the series).
In our opinion, platinum sensitiv-
ity should continue to be considered for 
clinical practice treatment planning and 
used as stratification factor in prospec-
tive clinical trials of SCLC second-line 
treatment.
Marcello Tiseo, MD, PhD
Medical Oncology Unit
University Hospital
Parma, Italy 
Luca Boni, MD, PhD
Clinical Trials Coordinating Center
Istituto Toscano Tumori
University Hospital Careggi
Firenze, Italy 
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Group (SWOG) trials of noncytotoxic 
molecular-targeted therapies in the 
platinum-treated SCLC population. We 
reported that in our pooled database, 
platinum sensitivity status was no lon-
ger as strongly associated with sub-
sequent survival after treatment with 
newer noncytotoxic agents, in contrast 
with what had been previously described 
with second-line cytotoxic therapies.
Tiseo et al. point to their own 
meta-analysis of six trials of second 
line therapy as evidence that platinum-
sensitivity status should continue to be 
considered for SCLC treatment plan-
ning and study stratification. However, 
we must point out that this meta-analysis 
was solely confined to trials of the cyto-
toxic topoisomerase inhibitor topotecan 
whereas our analysis was based on trials 
that predominantly evaluated noncyto-
toxic targeted agents. In fact, we agree 
with Kim and Mishima when they artic-
ulately emphasize this point by stating 
that our conclusions are correct “when 
noncytotoxic agents, such as molecu-
larly targeted agents, are used for sec-
ond line chemotherapy.” We, therefore, 
believe that our data set is even more rel-
evant to modern-day clinical trial design 
and planning of novel SCLC therapeu-
tics beyond that of cytotoxics.
Finally, we must emphasize that 
SWOG has done a remarkable job of 
consistently collecting the same data ele-
ments in its SCLC trials through the years. 
The availability of high quality, consistent 
data allows us to confidently pool our 
SWOG trials and expect that each data 
element is available for evaluation in our 
bivariate and multivariate models. Other 
pooled datasets or meta-analyses collect 
information from disparate trials that 
do not consistently share the same data 
elements, thus reducing confidence in 
the subsequent prognostic models.
Primo N. Lara, Jr., MD
David R. Gandara, MD
University of California Davis 
Comprehensive Cancer Center
Sacramento, CA 
Mary W. Redman, PhD
SWOG Statistical Center
Seattle, WA 
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In Response:
We were pleased to see that our 
recent article questioning the continued 
relevance of platinum-sensitivity sta-
tus in relapsed small cell lung cancer 
(SCLC) in the modern era has stimu-
lated a healthy debate on this issue. In 
our report, we highlighted our collective 
experience within Southwest Oncology 
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